The General Hospital Corporation;President and Fellows of Harvard College
发明人:
Nisarg J. Shah,Ting-Yu Shih,Angelo S. Mao,David J. Mooney,David T. Scadden
申请号：
US16708218
公开号：
US20200206333A1
申请日:
2019.12.09
申请国别(地区):
US
年份:
2020
代理人:
摘要：
Acute myeloid leukemia (AML) is a clonal disorder of hematopoietic stem and progenitor cells. It is a devastating disease with a poor prognosis and an average 5-year survival rate of about 30%. Disclosed herein are composition and methods for treating leukemia with a biomaterial comprising a polymer scaffold, a dendritic cell activating factor, a dendritic cell recruitment factor, and at least one leukemia antigen. The biomaterial-based vaccine disclosed herein promotes a potent, durable and transferable immune response against acute myeloid leukemia to prevent cell engraftment and synergizes with chemotherapy to prevent relapse.
